Fast-Her: Fasting Effects on Breast Cancer Treatment
ConditionMetastatic Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Minnesota
About this trial
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
Eligibility criteria
Qualifiers
Age ≥18 years
Histologically confirmed metastatic breast cancer
Menopausal or medically ovarian suppressed
Currently receiving capivasertib therapy (2 tablets twice daily, 4 days per week)
Disqualifiers
Type 1 diabetes mellitus
Uncontrolled type 2 diabetes (HbA1c >9.0%)
History of severe hypoglycemia
Eating disorders or contraindications to fasting
Trial design
Treatments tested in this trial
- Normal Eating
- Prolonged Fasting
Treatment groups
15 Participants
are divided into 2 treatment groupsLocations
1University of Minnesota55455, MinneapolisMinnesota, United States
Sponsors and collaborators
University of Minnesota
Lead sponsor
Source ClinicalTrials.gov